BTIG analyst Sean Lavin raised his price target on Exact Sciences to $130 and kept his Buy rating after its Q1 revenue beat and a raise in FY19 outlook. The analyst notes that with nearly all metrics outperforming in the quarter, he sees “little risk to the current momentum”, and believes that the management’s marketing / salesforce ramps should continue to be productive and lead to beats throughout the year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.